Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | XBP1 | P17861 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.32 |
| ▸ | MAPT | P10636 | 3/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | DRD4 | P21917 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6079087 | 0.87 | — | — | |
| SCHEMBL6078841 | 0.85 | F10 (0.42) | — | |
| SCHEMBL6078359 | 0.82 | ALDH1A1 (0.42) | TRPV4SMN1; SMN2LMNAALDH1A1KDM4E | |
| SCHEMBL4528724 | 0.80 | F10 (0.44) | — | |
| SCHEMBL6080130 | 0.79 | ALDH1A1 (0.39) | TRPV4SIGMAR1OPRM1ALDH1A1MAPT | |
| SCHEMBL4516479 | 0.79 | ALDH1A1 (0.39) | TRPV4SMN1; SMN2LMNAALDH1A1MAPT | |
| SCHEMBL7257489 | 0.78 | LMNA (0.43) | SIGMAR1OPRM1LMNAALDH1A1L3MBTL1 | |
| SCHEMBL6079709 | 0.77 | TRPV4 (0.38) | TRPV4SIGMAR1OPRM1ALDH1A1KDM4E | |
| SCHEMBL6079366 | 0.75 | F10 (0.49) | SMN1; SMN2LMNAALDH1A1MAPK1MEN1 | |
| SCHEMBL6078643 | 0.74 | F10 (0.41) | TRPV4SMN1; SMN2LMNAALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7122662-B2 | Tricyclic compound having spiro union | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2006-10-17 | — | — | US | disclosed |
| US-20050148769-A1 | Tricyclic compound having spiro union | MOCHIDA PHARMACEUTICAL CO., LTD. | 2005-07-07 | — | — | US | disclosed |
| US-6858599-B2 | Inhibitor for activated blood coagulation factor X | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2005-02-22 | — | — | US | disclosed |
| US-20040063716-A1 | Cholesterol biosynthesis inhibitors containing as the active ingredient tricyclic spiro compounds | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2004-04-01 | — | — | US | disclosed |
| US-20030045520-A1 | Tricyclic compound having spiro union | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2003-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063716-A1 | Cholesterol biosynthesis inhibitors containing as the active ingredient tricyclic spiro compounds | VKORC1, CYP46A1, TFPI | TRPV4 3055/4885SIGMAR1 2556/4885OPRM1 4006/4885 |
| US-20030045520-A1 | Tricyclic compound having spiro union | F2, TFPI, F11 | TRPV4 966/4885SIGMAR1 3298/4885OPRM1 3195/4885 |
| US-20050148769-A1 | Tricyclic compound having spiro union | TFPI, F2, F12 | TRPV4 911/4885SIGMAR1 3914/4885OPRM1 3525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.